Compare Seagate Technology Holdings PLC (STX) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Seagate Technology Holdings PLC vs Vertex Pharmaceuticals Incorporated — how do they compare? Seagate Technology Holdings PLC trades at $835.15 (market cap $181.54B), while Vertex Pharmaceuticals Incorporated trades at $529 (market cap $132.79B). The key difference: Seagate Technology Holdings PLC is the larger of the two by market cap, and Seagate Technology Holdings PLC pays a 0.37% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| STX | VRTX | |
|---|---|---|
Market Cap | $181.54B | $132.79B |
Sector | Technology | Health |
52-Week High | $1.09K | $529.65 |
52-Week Low | $154.43 | $376.62 |
Enterprise Value | $183.69B | $126.92B |
Dividend Yield | 0.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
STX trades at $812.76, down 4.71% in the last 24 hours, with technical indicators showing a bearish trend and key support at $758. The company reported strong Q2 2026 earnings, beating estimates with EPS of $5.71 versus $5.10 expected, driven by AI storage demand. Valuation ratios are elevated, with a P/E of 58.47 and P/S of 15.26, while profitability remains robust with a net income margin of 26.11%.
Outlook is positive due to AI-driven growth and analyst consensus, but high valuation and competitive pressures pose risks. The consensus price target is $1,130, offering ~39% upside, supported by 28 buy ratings. Investors should weigh strong fundamentals against premium pricing and market volatility.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Seagate Technology Holdings PLC
Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital
Read more on STX →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
